PROSTATE-SPECIFIC MEMBRANE ANTIGEN AND OTHER PROSTATIC TUMOR MARKERS ON THE HORIZON - 11/09/11
Doi : 10.1016/S0094-0143(05)70391-8
Résumé |
Adenocarcinoma of the prostate is the most prevalent malignancy in American men excluding skin cancer. In 1996, more than 317,000 new cases of adenocarcinoma are expected to be diagnosed, with more than 41,400 deaths attributable to it.74 An increase in public and professional awareness and in use of serum markers such as prostatic acid phosphatase and predominantly prostate-specific antigen (PSA) in part accounts for the rapid rise in the number of cases diagnosed during the past 8 years.
Le texte complet de cet article est disponible en PDF.Plan
| Address reprint requests to William R. Fair, MD, Memorial Sloan-Kettering Cancer Center, Urology Service, 1275 York Avenue, New York, NY 10021 This article is supported in part by The Carolan, Martell and Koch Foundations and the George M. O'Brien Prostate Cancer Research Center. |
© 1997
W. B. Saunders Company. Publié par Elsevier Masson SAS. Tous droits réservés.© 1994
© 1995
© 1995
© 1994
Vol 24 - N° 2
P. 439-450 - mai 1997 Retour au numéro
Article précédent
- THE USE OF PROSTATE-SPECIFIC ANTIGEN AS A SURROGATE END POINT IN THE TREATMENT OF PATIENTS WITH HORMONE REFRACTORY PROSTATE CANCER
- David C. Smith, Kenneth J. Pienta
- THE SOCIOECONOMIC IMPLICATIONS OF PROSTATE-SPECIFIC ANTIGEN SCREENING
- Ronald M. Benoit, Michael J. Naslund
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?